Home > Rheumatology > EULAR 2022 > Spotlight on Rheumatoid Arthritis > Preventive treatment with methotrexate benefits pre-RA patients with arthralgia

Preventive treatment with methotrexate benefits pre-RA patients with arthralgia

Presented By
Dr Doortje Krijbolder, Leiden University Medical Center, the Netherlands
Conference
EULAR 2022
Trial
TREAT EARLIER
Doi
https://doi.org/10.55788/d9b3d437
For the first time, a study demonstrated the benefit of arthralgia treatment with methotrexate before rheumatoid arthritis (RA) is diagnosed. Although the advancement to RA could only be delayed, the burden of disease was significantly reduced in this proof-of-concept study. The window of opportunity for the treatment of RA is often seen in early disease, as there is ample evidence that effective disease modification with disability reduction or prevention is possible [1,2]. One question that has not been answered yet is whether RA can be prevented in patients with arthralgia who are at risk for RA. “So far, 2 trials have been performed in this phase, but these found no prevention of RA. “This could depend on the chosen treatments or selected outcomes,” stated Dr Doortje Krijbolder (Leiden University Medical Centre, the Netherlands) [1]. The randomised, 2-year proof-of-concept TREAT EARLIER study tested methotrexate versus placebo for reduction o...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on